Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
Rhea-AI Summary
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.
The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RLAY declined 4.55%, reflecting a moderate negative market reaction. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $603M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 7, 2025.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) report Q2 2025 earnings?
What is Relay Therapeutics' (RLAY) main business focus?
How can investors access Relay Therapeutics' Q2 2025 earnings report?
What stock exchange is Relay Therapeutics (RLAY) listed on?
